Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
27 hedge funds and large institutions have $4.43M invested in Medicenna Therapeutics Corp. Common Shares in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% less funds holding
Funds holding: 28 → 27 (-1)
3.6% less ownership
Funds ownership: 17.39% → 13.78% (-3.6%)
45% less capital invested
Capital invested by funds: $8.12M → $4.43M (-$3.68M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$303K |
| 2 |
Renaissance Technologies
New York
|
+$80.1K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$68.7K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$65.4K |
| 5 |
LBA
Letko, Brosseau & Associates
Montreal,
Quebec, Canada
|
+$42.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$270K |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$124K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$40.1K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$23.5K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$5.8K |
MDNA Hedge Fund Activity: Q4 2022 in Review
27 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q4 2022, worth a combined $4.43M — down 45% from $8.12M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MDNA positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 3 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $303K. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $270K sold.
- 27 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q4 2022, down from 28 in Q3 2022.
- Funds reported $4.43M of Medicenna Therapeutics Corp. Common Shares stock for Q4 2022, down 45% quarter-over-quarter.
- 5 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q4 2022 and 4 closed out, a net change of +1 holder.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q4 2022 was AIGH Capital Management, an estimated $303K added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q4 2022 was Granite Point Capital Management, an estimated $270K sold.
Based on aggregated 13F filings for Q4 2022.